Preparation for treatment and prophylaxis of mastitis in cows at onset of lactation period and in dry cows

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

 

The invention relates to the field of veterinary medicine, can be used for the treatment and prevention of mastitis in the dry period and during startup.

Mastitis - inflammation of the mammary gland, resulting in different physiological periods in cows.

Mastitis in cows is widely distributed at the end of lactation, during start-up and dry period, as well as after birth.

The number of known analogue medications used to treat mastitis in cows. For example, Pesticid /1/, Mastison And /2/, Mastison B /3/, Mastison E /4/, Pesticid /5/, Furagin /6/, Master - 30 /7/.

However, these drugs contain antibiotics and sulfanilamide, which currently has a number of negative sides (the rapid development of resistant strains of microorganisms, inhibition of the protective mechanisms of the microorganisms and the emergence of mycotic mastitis etiology, occurrence of cases of allergies and anaphylaxis in animals and humans).

The prototype of the invention is the preparation Dipomat /8/.

Part of the preparation Dipomat the following:

Dioxidine 2%;

Furatsilin 0,04%;

Beeswax 5%;

Vaseline oil - the rest.

The drug is a homogeneous yellow oily liquid. Dioxidine in combination with furatsilina gives good effect against gram-positive and gram-negative microorganisms, Academy of Sciences of Arabov, the simplest.

The main disadvantage of the prototype low therapeutic efficacy due to the fact that the microflora isolated from the mammary gland of cows, is slabocuvstivenami or insensitive to active components (dioxidine, furacilin).

Another disadvantage is the need for repeated administration in the cistern of the udder (4 or more times), which increases labor costs veterinary specialists, negatively affects the mucous membranes of the nipple channel and tanks of the breast.

The technical result of the invention is to increase therapeutic and prophylactic efficacy, reducing the complexity of the treatment and prevention of mastitis in cows during the run and snags.

In addition, resulting in improved milk quality, increase yields, reduced the number of culled animals and decrease the cost of treating sick animals, cured cows in late lactation and start running only healthy cows, to the processes of involution of the mammary gland were normal.

This goal is achieved by the application of composite preparation consisting of the following components, wt%:

Furacilin - 0,4-0,6;

Dioxidine - 0,8-1,2;

Beeswax - 4-6;

Sunflower oil - the rest.

The optimal ratio to the components, is the following (wt.%):

Furacilin - 0,5;

Dioxidine - 1;

Beeswax - 5;

Sunflower oil - the rest.

Dioxidine-1,4-di-N-oxide 2,3 bio(oxymethyl)finokalia - chemotherapeutically the drug is characterized by activity in infections caused by gram-positive and gram-negative bacteria 191.

Furacilin-1-5-nitrophenylacetylene-1,3,4-triazole /10/.

Furacilin is derived 5-nitrofurantoina. He has a strong antimicrobial activity against Staphylococcus, Streptococcus, E. and hay Bacillus, various species of Salmonella, Proteus vulgar, microorganisms of the genus Shigella in a concentration of 0.2-13,0 g/ml. the Mechanism of antimicrobial action furacilin due to a violation of DNA synthesis in microbial cell. Furacilin belongs to the class of low-toxic substances sixth series. To him unlike antibiotics slow the development of resistance of microorganisms. He does not suppress the natural protective mechanisms of the body of an animal, stimulates the phagocytic activity of leukocytes, udder secretions, blood.

The composition of the claimed preparation also includes beeswax, which helps slow the absorption of the drug, thereby increasing the validity of the drug, which is an important moment in the prevention and therapy in the period starts the a and deadwood. Sunflower oil plays a role filler.

The preparation is applied as follows. In heated to 38-40°the form is entered into the mammary gland of cows, as affected, and free from mastitis share, nipple through the channel at a dose of 5 ml once with a syringe. Thus, the use of the drug leads to reduce the complexity. Prototype (Dipomat) is injected repeatedly into the cistern of the udder (4 or more times), which increases labor costs veterinary specialists and, in addition, negatively affects the mucous membranes of the nipple channel and tanks of the breast.

The drug is manufactured as follows (in brackets - specify in wt.% the number of components). Sunflower oil (rest) and beeswax (5%) perenapravitsya at a temperature of 60°With, then added activetestsuite substance - Furacilin (0.5%) and Dioxidine (1%).

Experiments to verify the effectiveness of the drug was carried out at the experimental station of the VSAU, GPOP VNIIS Ramon district of Voronezh region, Federal 11113 "Kirov" novousmansky district of Voronezh region, DWF "Petrovsky" Dobrinsky district of Lipetsk region.

The essence of the proposed technical solution is illustrated by examples.

Example 1. Irritant effect on the mammary gland of cows.

Were selected 3 clinically healthy lactating cows. Pre the Arat in the optimal ratio of components (Furacilin - 0,5; Dioxidine - 1; beeswax - 5; sunflower oil - the rest), heated to a temperature of 38°in an amount of 5 ml was injected intracisternally in the left front portion of the udder after the preliminary divania secretion and processing of the nipple 70° ethyl alcohol. In the front right of the fraction of the drug is not introduced, she served as a control. Before the introduction of the drug and through 3, 6, 12, 24, 48, 72 and 96 h were performed General clinical examination of animals, breast, reaction with 2% solution of masticina. In the laboratory calculated the number of somatic cells and responsive to the sample solution. The results of the experiment are presented in table 1.

Table 1

Change the content of somatic cells in the udder secretions of healthy cows after intracisternal the introduction of the proposed drug.
Part of the udderTime studies
before the introduction of3 hours6 hours12 hours24 hours48 hours72 hours
the amount To thousand/ml
Left front (experience)USD 376.6±12,1425,8±13,6710,3±13,21234,3±42,11473,3±the 15.6734,6넘,5 398,6±10,9
Right front (control)377,2±11,2477,0±12,3579,3±20,7639,3±14,3676,0±14,9568,6±12,1382,0±11,2

In the study of the secret with a 2% solution of masticina doubtful reaction and the increase of somatic cells was observed in all animals after 3 hours after drug administration. By 24 hours after administration of the drug is observed a maximum increase of somatic cells to 1473,3 thousand/ml, and by 72 hours the number of somatic below 500 thousand/ml

Example 2. The effectiveness of the proposed drug for the treatment of subclinical mastitis in cows in the dry period.

They selected four groups of cows of Holstein-Friesian breed second-fourth lactation. Were diagnosed according to the research results with 2% solution of masticina.

Cows experimental groups were injected claimed the drug intracisternal a single dose of 5 ml of warmed up to 38°With the form in different ratios of active components, wt.%:

Recipe 1.

Furacilin - 0,5;

Dioxidine - 1;

Wax - 5;

Sunflower oil - the rest.

Recipe 2.

Furacilin - 0,4;

Dioxidine - 0,8;

Wax - 4;

Sunflower oil - the rest.

Recipe 3.

Furacilin - 0,6;

Dioxidine - 1,2;

Wax - 6;

Sunflower oil - the rest.

Animals of the control group were injected with Dipomat intracisternal at a dose of 5 ml of warmed up to 38°With the form in accordance with the instruction to the drug /9/.

The animals were monitoring therapeutic efficacy of the drug was determined by the incidence of cows after calving subclinical mastitis. The results of the experiment are shown in table 2.

Table 2

therapeutic efficacy of the proposed drug in subclinical mastitis in cows
MedicationNumberRecoveredLeft sick
Cowssharescows%shares%cows%shares%atrophy%
Declare, REC.901308695,811991,544,2118,5--
Dipomat9921676of 76.816174,5 2323,25123,641,9
Declare, REC.821247389,010584,6911,01915,4--
Declare, REC.8516281for 95.314891,44the 4.7148,6--

From table 2 it follows that the best therapeutic effect achieved with the use of a composition dioksidina, furacilin and beeswax in the ratio of 1.0:0.5 to:5,0.

Example 3. The effectiveness of the proposed drug for the prevention of subclinical mastitis in cows in the dry period.

They selected five groups of cows of Holstein-Friesian breed 2-4 lactation. Were diagnosed according to the research results with 2% solution of masticina.

Animals of the first group was administered the claimed preparation in the recipe 1:

Furacilin - 0,5;

Dioxidine - 1;

Wax - 5;

Sunflower oil - the rest.

The drug was administered intracisternally a single dose of 5 ml of warmed up to 38°.

Animals of the third group was administered the claimed preparation in the recipe 2:

Furacilin - 0,4

Dioxidine - 0,8;

Wax - 4;

Sunflower oil - the rest.

The drug was administered intracisternally a single dose of 5 ml of warmed up to 38°.

The animals of the fourth group was administered the claimed preparation in the recipe 3:

Furacilin - 0,6;

Dioxidine - 1,2;

Wax - 6;

Sunflower oil - the rest.

The drug was administered intracisternally a single dose of 5 ml of warmed up to 38°.

The fifth group of animals served as negative control. For animals conducted surveillance, prophylactic efficacy of the drug was determined by the incidence of cows after calving, subclinical mastitis.

Table 3

The effectiveness of the proposed drug and the prototype for the prevention of subclinical mastitis in cows in the dry period
MedicationNumberNot sick mastitisIll mastitis
cowssharescows%shares%cows%shares%atrophy%
Declare, REC.4017 3997,515296,812,553,2--
Dipomat301182686,79580,5413,32319,5--
Declare, REC.3815234to 89.5135and 88.8410,51711,2--
Declare, REC.401493997,514396,012,564,0--
Control481893368,712666,61531,35730,263,2

Thus, studies have shown high therapeutic and prophylactic efficacy of the proposed drug. The use of the proposed technical solution can significantly reduce labor costs veterinary specialists.

the sources of information

1. Mastered. Instruction for use. Approved by the chief veterinary Department Ministry of agriculture of the USSR 17.08.1977,

2. Mastison A. Guidance on the application. Approved by the chief veterinary Department Ministry of agriculture of the USSR, 25.10.1982

3. Mastison B. Guidance on the application. Approved by the chief veterinary Department Ministry of agriculture of the USSR 22.10.1982,

4. Mastison that is, the Instruction for use. Approved by the chief veterinary Department Ministry of agriculture of the USSR 22.10.1982,

5. Balkovoy I.I. the Effectiveness of the fight against mastitis cows //Issues of veterinary pharmacy and pharmacotherapy: proc. Dokl. Uses. scientific and practical use. proc. - Riga, 1982. - S-75.

6. The Savostin A. N. The use of purachina for the treatment and prevention of subclinical mastitis in cows during the dry period: author. dis.. Kida. wet. Sciences / Animosity. - Voronezh, 1988 - 24 C.

7. The Polyantsev NI Treatment of subclinical mastitis / Polyantsev NI // veterinary - 1997. No. 12. - p.37-39.

8. Dipomat - antimastit drug. Standing instruction for use. Approved by the veterinary Department of the Ministry of agriculture of the Russian Federation 29.07.02. he

9. Instructions for use dioksidina, the Ministry of health of the USSR. 23.12.1982,

10. Morgunov VI Pharmaco-Toxicological properties furacilin. / The dissertation on competition of a scientific degree of the candidate of veterinary Sciences. - Voronezh, 1922.

Drug for the treatment and prevention of mastitis in cows during zapuska deadwood, containing dioxidine and beeswax, characterized in that it further comprises furacilin and sunflower oil in the following ratio of components, wt.%:

Furacilin0,4-0,6
Dioxidine0,8-1,2
Beeswax4-6
Sunflower oilThe rest of it.



 

Same patents:

FIELD: organic chemistry, antibiotics, pharmacy.

SUBSTANCE: invention relates to 9a-N-[N'-(phenylsulfonyl)carbamoyl]-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A that are new semisynthetic macrolide antibiotics relating to class of azalides showing antibacterial effect and describing by the general formula (1):

wherein R1 means hydrogen atom (H), (C1-C4)-alkyl or halogen atom; R means H or cladinosyl radical, and to their pharmaceutically acceptable salts. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof.

EFFECT: improved preparing method, valuable medicinal properties of derivatives.

16 cl, 2 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: method involves covering lesion focus with cell containing dialysis solution composed of Dimexid, antibiotic, 0.1% potassium furagin and 25% glucose solution taken in 1:4:3:2 proportion. The cell is fixed on teeth with ligature. Cell wall adjacent to gingiva is covered with semipermeable Cuprofan membrane and the opposite wall with latex rubber. Dialysis is carried out 20 min long twice a day.

EFFECT: enhanced effectiveness of treatment; retained natural protection factors; reduced edema and inflammation manifestations.

Modified chitosan // 2269542

FIELD: organic chemistry of natural compounds, chemical technology, medicine.

SUBSTANCE: invention relates to the group of chitosan-containing compounds. Invention relates to synthesis of modified chitosan of the following structure: wherein n = 150-1400. The modified chitosan possesses the bactericidal activity, in particular, antituberculosis activity.

EFFECT: valuable medicinal properties of modified chitosan.

1 tbl, 1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with technique of revaccination in adults against diphtheria and tetanus under conditions of Far North. For this purpose one should form a group of people vaccinated more than 10 years ago to vaccinate them in February. The method leads to increased efficiency of vaccination due to decreased duration of vaccination period.

EFFECT: higher efficiency of revaccination.

7 ex

FIELD: medicine, obstetrics.

SUBSTANCE: one should conduct antibacterial therapy 3 mo before planned pregnancy consisting of preparations of tetracyclinic group or macrolides in combination with nystatin and metronidasol to continue it since the first day of menstrual cycle and, also, it is necessary to perform correction of vaginal biocenosis, and about 3-4 wk after therapy carried out for 2 next mo before planned pregnancy starting, also, since the first day of menstrual cycle - metabolic therapy; At the onset of pregnancy one should conduct courses for preventing placental deficiency dealing with introduction of preparations that improve uterine-placental circulation, and preparations that improve rheological properties of blood and vitamin-metabolic therapy or the same preparations, and additionally - introduction of macrolides ad viferon rectally in case of activation of chlamydial infection. The present innovation enables to sanitize uterine cavity, improve uterine-placental circulation, restoration of placental tissue structure that, in its turn favors the birth of healthy generation.

EFFECT: higher efficiency of prophylaxis.

1 cl, 9 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: medicinal formulation possessing the bacteristatic effect consists of a core comprising the following components, wt.-%: clarithromycin, 40.0-80.0; polyvinylpyrrolidone, 3.0-10.0; sodium lauryl sulfate, 2.0-5.0; sodium croscarmelose, 4.0-10.0; aerosil, 0.5-2.0; magnesium stearate, 0.5-2.0, and microcrystalline cellulose, 10.0-31.0. Also, the medicinal formulation consists of envelope comprising the following components, wt.-%: hydroxypropylmethylcellulose, 30.0-70.0; polyethylene glycol, 12.0-22.0; titanium dioxide, 11.0-20.0, hydroxypropylcellulose, 2.0-10.0, dye yellow quinoline, 1.0-4.0, and vanillin, 1.0-4.0. Also, invention describes a method for preparing the medicinal formulation by wet granulation followed by tableting and applying the envelope from an aqueous suspension. Prepared tablets show the necessary mechanical strength, insignificant scattering index by mass (± 3.5%) and dissolving 88-91% for 30 min.

EFFECT: improved and valuable properties of medicinal formulation.

3 cl, 2 tbl

FIELD: medicine, gynecology, surgery.

SUBSTANCE: one should introduce 3.5%-chitosan ascorbate gel into fistulous channel that contains metronidasol at the dosage of 2 mg/ml, at the volume up to 20 ml once/2 d till complete fistula's closing. The present innovation enables to activate reparative processes and fistulous epithelization that favors for closing fistulous channel in earlier terms.

EFFECT: higher efficiency of therapy conducted.

2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with application of pleuromutilin derivatives, that is valnemulin and thiamulin, for transdermal treatment of bacterial diseases, in particular those induced by Dichelobacter nodosus, Fusobacterium necrophorum, Bacteriodes nodosus and Bacteriodes melamnogenicus, for manufacturing medicinal preparation or as an active ingredient of medicinal preparation of the same indication and corresponding method for transdermal treatment of diseases, for example foot rot. It has been detected the capacity of antibiotics to penetrate skin and enter either plasma or blood at concentrations being efficient against systemic bacterial infections, so, medicinal preparation could be designed in the form of ointment, cream, solution, shampoo, powder and spray.

EFFECT: higher efficiency of application.

9 cl, 1 tbl

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes preparation that comprises the immunoelectrophoretically pure secretory immunoglobulin A isolated from whey milk and/or colostrum of immunized ungulate animals and pharmaceutically acceptable vehicles. The base preparation (substance) comprises 6-12% of secretory immunoglobulin A at pH 4-8, an anti-complementary activity at least 10 mg of protein, not activating 2 CH50, protects in >70% against corresponding infections (in infection macroorganism in doses ≥10 ID50), shows areactogenic property in intravenous administration, can comprise stabilizing additives in the total concentration 4%, not above. The preparation possesses high purity, low anti-complementary activity, stable in storage, useful for oral, parenteral and topical using and possesses therapeutic activity with respect to microorganisms and viruses against which humans and animals immunization have been carried out. Invention can be used in treatment and prophylaxis of immunodeficiency states, bacterial and viral infections in humans and animals.

EFFECT: valuable medicinal and veterinary properties of preparation.

9 cl, 1 tbl, 10 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating puerperal endometritis in cows. One should introduce the foam into uterine cavity that appears after interacting with warm water containing 10 U oxytocin and a suppository that includes medicinal substances reduced up to amorphous state. Moreover, components in a suppository are in the following ratio, g (weight%): potassium iodide 1.5 (5.4), ephedrine hydrochloride 0.5 (1.8), furacillin 0.5 (1.8), metronidazole (trichopol) 1.5 (5.4), proserine (prostigmin) 0.06 (0.2), analgin 0.5 (1.8), sodium bicarbonate 9.0 (32.7), potato starch 4.0 (14.6), common salt 1.5 (5.4), citric acid 6.9 (25), calcium stearate 0.3 (1.1), 20%-alcoholic solution of MGD-2 emulsifier or MGD-2-similar one 1.3 (4.8). The innovation provides higher efficiency of local impact of medicinal substances upon pathogenic uterine microflora.

EFFECT: higher efficiency.

1 cl, 1 tbl

FIELD: veterinary medicine.

SUBSTANCE: the present innovation deals with treating and preventing acute and chronic endometritis, vaginitis and balanoposthitis. For this purpose, it is necessary to introduce into an organ's cavity a foam-inducing preparation that contains crystalline substances, that is a foam-inducing suppository or the mixture of substances for its preparing and, also, 100.0 ml 1%-common salt solution heated up to animal body temperature, at the following ratio of suppository components or mixture for its preparing, that provides liquid of alkaline reaction at dissolving, g (weight%): potassium iodide 1.5 (6.3), potato starch 4.0 (16.8), furacillin 0.5 (2.1), metronidazole (trichopol) 1.2 (5.0), analgin 0.5 (2.1), citric acid 6.2 (26.0), sodium bicarbonate (dietary soda) 8.0 (33.7), calcium stearate 0.2 (0.9), calcium carbonate (deposited chalk) 0.5 (2.1), 20%-alcoholic solution of MGD-2 emulsifier or any other similar one 1.2 (5.0). The innovation provides prolonged complex anti-infectious, antiphlogistic, analgesic impact upon animal body, activation of protective and endocrine systems.

EFFECT: higher efficiency of prophylaxis and therapy.

3 cl, 1 dwg, 1 tbl

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, stomatology.

SUBSTANCE: for treating one should apply successively 3%-hydrogen peroxide solution followed by 1%-silver nitrate solution. This provides high antiseptic effect in combination with minimal dental dyeing with solver nitrate solution.

EFFECT: higher efficiency.

6 ex, 1 tbl

FIELD: pharmaceutics.

SUBSTANCE: the innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.

EFFECT: higher efficiency of manufacturing.

1 cl, 3 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for preventing and treating foot rot in animals includes the product of mustard seeds processing - allyl mustard oil and an emulsifier - an aqueous bischofite solution of natural mineral at the following ratio of components, weight%: allyl mustard oil 0.01-1.0, bischofite 2.0-20.0, water - the rest. The suggested composition is highly efficient and provides improved curative effect after 5-10 foot baths in animals.

EFFECT: higher efficiency.

2 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to methods for preparing chemotherapeutic preparation comprising biologically active iodine. Method for preparing bismuth iodide sulfamide is carried out by addition of bismuth basic nitrate to potassium iodide an aqueous solution and heating the reaction mass in acid medium up to 75-80oC. Then streptocide is added and heating is continued up to 100-105oC, kept at this temperature up to the melt formation followed by cooling and grinding. Method provides preparing the end product with the content of elemental iodine 10.8-11.0% by the wasteless technology for a single stage.

EFFECT: improved preparing method.

3 ex

FIELD: medicine; medical engineering.

SUBSTANCE: means is composed of spherical and close-to-spherical 500-3000 mcm large microgranules. Microgranule matrix has at least one cross-linked polymer and fillers. The cross-linked polymer is taken as sodium alginate, or gelatin, or pectin, or carraginan, or agar-agar, or sodium salt of carboxycellulose, or copolymer of acrylic acid and butylacrylate, or their mixtures. The fillers are hyperosmolar, antiseptic, anesthetic and, when required, antioxidant compounds. Method involves placing microgranules into pyoinflammatory lesion focus through postoperative or fresh wound. Wound cavity space is filled with microgranules to not more than one-half of its volume. Then the wound is drained and covered with antiseptic bandage. The granules and bandage are changed once a day during 2-3 days.

EFFECT: enhanced effectiveness of treatment; prolonged drug concentration support in wound.

6 cl,1 tbl

The invention relates to medicine and can be used for the treatment of angina

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating puerperal endometritis in cows. One should introduce the foam into uterine cavity that appears after interacting with warm water containing 10 U oxytocin and a suppository that includes medicinal substances reduced up to amorphous state. Moreover, components in a suppository are in the following ratio, g (weight%): potassium iodide 1.5 (5.4), ephedrine hydrochloride 0.5 (1.8), furacillin 0.5 (1.8), metronidazole (trichopol) 1.5 (5.4), proserine (prostigmin) 0.06 (0.2), analgin 0.5 (1.8), sodium bicarbonate 9.0 (32.7), potato starch 4.0 (14.6), common salt 1.5 (5.4), citric acid 6.9 (25), calcium stearate 0.3 (1.1), 20%-alcoholic solution of MGD-2 emulsifier or MGD-2-similar one 1.3 (4.8). The innovation provides higher efficiency of local impact of medicinal substances upon pathogenic uterine microflora.

EFFECT: higher efficiency.

1 cl, 1 tbl

Up!